Literature DB >> 6476782

Biochemistry and clinical relevance of lipoprotein X.

S Narayanan.   

Abstract

Lipoprotein X (LP-X) is an abnormal lipoprotein that appears in the sera of patients with obstructive jaundice and is thus a marker for cholestasis. The presence of LP-X in serum does not allow discrimination between intra- and extra-hepatic cholestasis. In addition LP-X is present in the plasma of patients with familial plasma lecithin: cholesterol acyl transferase (LCAT) deficiency. It is a spherical particle that aggregates strongly. Phospholipids and unesterified cholesterol make up the bulk of LP-X, which is a low density lipoprotein. Protein, cholesterol esters, and triglycerides together make up 12 percent of the composition of LP-X. Lithocholic acid is the major bile acid in LP-X. Three species of LP-X have been isolated (LP-X1, LP-X2 and LP-X3). Because of its aggregating properties, LP-X complexes with enzymes, such as alkaline phosphatase. Electrophoretic and immunochemical methods are available for assay of LP-X. The fact that bile lipoprotein can be converted to LP-X by addition of albumin, and LP-X can be converted to bile lipoprotein by the addition of bile salts may suggest that the integrity of the LPX molecule depends on a certain critical bile salts to albumin ratio. Phospholipase in plasma is implicated in the catabolism of LP-X. The role of LP-X in cholestasis is apparently related to the removal of free cholesterol from the circulation as a consequence of its aggregating properties.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6476782

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  6 in total

1.  Effect of lipoprotein-X on lipid metabolism in rat kidney.

Authors:  K O; M Ly; D Z Fang; J Frohlich; P C Choy
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

2.  LCAT Enzyme Replacement Therapy Reduces LpX and Improves Kidney Function in a Mouse Model of Familial LCAT Deficiency.

Authors:  Boris L Vaisman; Edward B Neufeld; Lita A Freeman; Scott M Gordon; Maureen L Sampson; Milton Pryor; Emily Hillman; Milton J Axley; Sotirios K Karathanasis; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2018-12-18       Impact factor: 4.030

3.  A novel in vivo lecithin-cholesterol acyltransferase (LCAT)-deficient mouse expressing predominantly LpX is associated with spontaneous glomerulopathy.

Authors:  Xianghong Zhu; Andrew M Herzenberg; Mohammad Eskandarian; Graham F Maguire; James W Scholey; Philip W Connelly; Dominic S Ng
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

4.  Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis.

Authors:  Eric J Brandt; Shane M Regnier; Edward Ky Leung; Sharon H Chou; Beverly W Baron; Helen S Te; Michael H Davidson; Robert M Sargis
Journal:  Clin Lipidol       Date:  2015-08-01

5.  Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay.

Authors:  Shimpi Bedi; Erwin Garcia; Elias J Jeyarajah; Irina Shalaurova; Maria Camila Perez-Matos; Z Gordon Jiang; Robin P F Dullaart; Steven P Matyus; William J Kirk; James D Otvos; W Sean Davidson; Margery A Connelly
Journal:  J Clin Med       Date:  2020-09-10       Impact factor: 4.241

Review 6.  High-Density Lipoproteins and the Kidney.

Authors:  Arianna Strazzella; Alice Ossoli; Laura Calabresi
Journal:  Cells       Date:  2021-03-31       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.